
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
Novasep selects Thierry van Nieuwenhove as new president of the synthesis business unit.
Van Nieuwenhove holds a Master's degree in chemistry and biochemistry from the Catholic University of Louvain, Belgium. Van Nieuwenhove joins Novasep from Ajinomoto-Omnichem, a European synthetic molecules custom manufacturing organization, where he held positions as director, general manager, and member of the board.
Source:






